Latest Breaking News On - ப்ரொஃபெஸர் ஆஃப் மருத்துவ அறிவியல் - Page 1 : comparemela.com

The round was led by Taiwan-based Ruentex Group. The company intends to use the funds to complete IND-enabling preclinical studies and initiate a Phase 1/2 clinical trial of RB-100 in 2021 and continue the development of its proprietary, DNA-based MYO (Make Your Own) Technology™ antibody delivery platform, with the goal of advancing a lead candidate into the clinic within two years.   Co-founded by HIV expert, David D. Ho, M.D., founding scientific director of the Aaron Diamond AIDS Research Center and Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons, and Yaoxing Huang, Ph.D., Associate Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons, and led by Neal N. Padte, Ph.D., Chief Operating Officer and Chief Development Officer, and Rachel A. Liberatore, Ph.D., Director of Research and Development, RenBio is a preclinical biotechnology company developing novel antiviral antibody therapeutics and

Columbia universityNew yorkUnited statesSouth africaNealn padteYaoxing huangRachela liberatoreVagelos college of physiciansRuentex groupResearch centerYour own technologyProfessor of medical sciencesLewis bockiusColumbia university vagelos college of physiciansNew york basedTaiwan based ruentex